Neonatal Anti-seizure Medication Exposure and Long-term Neurological Outcomes

Markus Leskinen MD, PhD*[a,c], Volmar Kaipainen BSc*[a,d], Mine Öğretir MSc[a,e],
Marjo Metsäranta MD PhD[a,c], Matti Hero MD PhD[a,c], Samuli Rautava MD PhD[a,c],
Miika Koskinen DSc[a,b,c]

Affiliations: [a]Pediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland, [b]Diagnostic Center, Helsinki University Hospital, Helsinki, Finland, [c]Faculty of Medicine, University of Helsinki, Helsinki, Finland, [d]Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland, and [e] Computer Science Department, Aalto University, Espoo, Finland

Address correspondence to: Markus Leskinen, Department of Neonatology, New Children's Hospital, P.O. Box 347, 00029 HUS, Finland, markus.leskinen@hus.fi

Short title: Neonatal anti-seizure medication neurological outcomes

Conflict of Interest Disclosures (includes financial disclosures): The authors have no conflicts of interest relevant to this article to disclose.

Funding/support: The Foundation for Pediatric Research (Finland), the Association of Friends of the University Children's Hospitals (Lastenklinikoiden Kummit ry), and internal institutional funding.

Role of Funder/Sponsor (if any): The Foundation for Pediatric Research and The Association of Friends of the University Children's Hospitals had no role in the design and conduct of the study.

Data Sharing Statement: Deidentified individual participant data will not be made available.

Abbreviations:

ASM   anti-seizure medication
HIE   hypoxic-ischemic encephalopathy
HR   hazard ratio
HUS   Helsinki University Hospital
IVH   intraventricular hemorrhage
NICU   neonatal intensive care unit

What's known on This Subject
Anti-seizure medications (ASM) are widely used in neonatal intensive care, but there is limited evidence for their long-term outcomes. Phenobarbital is the only ASM approved for use in neonates, but it has been linked with adverse effects. Other ASMs are used off-label in infants.

What This Study Adds

By using real world data we showed increased hazard ratios for epilepsy, visual impairment and intellectual disability in infants exposed to phenobarbital. Although no dose-dependent relationship was observed, higher maximal plasma phenobarbital concentrations were associated with increased hazard ratios.

Contributors Statement Page

Dr Markus Leskinen contributed to conceptualization of the study, performed literature searches and contributed to interpretation and writing (drafting and editing).

Volmar Kaipainen conducted data analyses, contributed to data curation, interpretation, software, visualization, and writing (drafting and editing).

Mine Ögretir contributed to data analyses, curation, software and writing (review and editing).

Drs Marjo Metsäranta, Matti Hero and Samuli Rautava contributed in conceptualization of the study and writing (review and editing).

Dr. Miika Koskinen M.K. conceptualized the study, supervised and administrated the project, interpreted and validated the data, acquired funding and critically reviewed and revised the manuscript.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Abstract

Objective

There is limited evidence for Anti-seizure medication (ASM) safety and long-term outcomes in neonates. Phenobarbital is the only ASM accepted by FDA for neonatal use, but it has been linked with adverse effects. Other ASMs are used off-label in neonates. We wanted to examine links between neonatal ASM exposure and later neurological outcomes.

Methods

We performed a retrospective observational study of 18,548 infants in intensive care, examining links between ASM exposure and neurological outcomes over follow-up period of median 4.5 years. The clinical data included comprehensive maternal, perinatal, and medication data. Multivariable cause-specific Cox models were used to estimate hazard ratios (HRs) for phenobarbital, levetiracetam, midazolam, and fosphenytoin exposure.

Results

Exposure to the median cumulative dose of phenobarbital was associated with increased HR for epilepsy (HR 1.35; 95% CI, 1.11–1.62) visual impairment (HR 1.20; 95% CI, 0.99–1.45), and intellectual disability (HR 1.18; 95% CI, 0.99–1.41). In contrast, levetiracetam was associated with smaller risk increases for cerebral palsy (HR 1.13; 95% CI, 1.03–1.23), epilepsy (HR 1.14; 95% CI 1.05–1.24) and visual impairment (HR 1.18; 95% CI 1.11–1.26).

We did not find evidence of a dose-dependent phenobarbital effect, but increased maximum concentrations were associated with elevated hazard ratios for cerebral palsy (HR 1.48; 95% CI, 1.07–2.06) and epilepsy (HR 1.64; 95% CI, 1.14–2.35).

Conclusion

The results align with previous findings linking phenobarbital to neurodevelopmental harm and emphasize the need for its cautious use in neonates. Levetiracetam had more favorable safety profile.

1   Introduction

Neonatal intensive care relies heavily on pharmacological interventions and polypharmacy is

common. Due to low patient numbers and inherent challenges of conducting pharmacological

research in infants, many of the used medications are either off-label[1,2] or lack robust

evidence regarding their long term safety and efficacy. Recently, the utilization of clinical

real-world data in pharmaceutical research has garnered increasing interest for its use in

evaluating the effectiveness and safety of medication, particularly in situations where

traditional large-scale clinical trials are difficult to design or are otherwise challenging.

Seizures are common emergency in Neonatal intensive care units (NICUs) affecting 1–5

infants per 1000 live births. In high income countries the most common etiologies include

hypoxic-ischemic encephalopathy, ischemic stroke, and intracranial hemorrhage. Prompt

treatment with anti-seizure medication (ASM) is critical to minimize brain injury, but

evidence regarding the optimal choice of ASM and their long-term effects remains limited.[3,4]

Currently phenobarbital is the only ASM approved by the FDA for use in neonates and

remains the first-line treatment in most settings.[4,5] Other anti-seizure medications, such as

fosphenytoin, levetiracetam, and midazolam are used off-label in this population. There are

limited number of randomized controlled trials favoring phenobarbital over phenytoin and

levetiracetam[6,7] whilst some studies suggest comparable efficacy between phenobarbital and

levetiracetam.[8,9] Despite its widespread use, phenobarbital has been linked with adverse

effects in infants, with hypotension and respiratory depression among the most frequently

reported acute complications.[3] Evidence regarding its long-term effects is sparse typically

limiting to the first two years of life. Experimental animal studies have reported concerning

findings, including neuronal apoptosis, altered synaptic maturation, and changes in long term

behavior, learning and memory,[10–12] but currently there are limited data from humans.

Postnatal exposure to phenobarbital has been associated with cognitive decline in humans[13,14]

but due to coexisting hypoxic-ischemic injury and/or the effects of repeated seizures on many

of the infants receiving phenobarbital, causality is difficult to assess. Phenobarbital was also

previously used to treat febrile seizures, and in this setting it depressed cognitive performance

of children randomized to receive phenobarbital.[15]

Levetiracetam, by contrast, demonstrates a favorable safety margin, with most reported

adverse effects considered clinically manageable.[16,17] One retrospective study found worse

neurodevelopmental outcomes in infants treated with phenobarbital than levetiracetam.[18]

The favorable safety profile has contributed to the increasing off-label use of levetiracetam

for neonatal seizures, but its optimal use has remained elusive.[19]

Fosphenytoin, historically a second line therapy for treating neonatal seizures, has seen a

decline in use over recent years.[20] The adverse effects of fosphenytoin include arrhythmia,

hypotension and central neural system depression.[6] In animal studies it has also caused

apoptosis and synaptic disruption.[11,12]

Midazolam is typically reserved as a third-line therapy for refractory seizures, yet most

studies assessing its efficacy in neonates are limited by small sample sizes and inconsistent

findings.[21,22] As a potent benzodiazepine, midazolam carries risks of sedation and need for

mechanical ventilation,[23] and increased risk for poor early neurological outcome in patients

sedated with midazolam as compared with morphine has been reported.[24]

Against this backdrop, we aimed to investigate the long-term neurological outcomes

associated with neonatal ASM exposure. By linking comprehensive real-world NICU data on

ASM administration with registry-based follow-up information concerning major neurologic

morbidities—including cerebral palsy, epilepsy, autism spectrum disorders, and

developmental problems—we were able to assess population-level clinical outcomes

extending well beyond the common two-year follow-up period.

Materials and Methods

Study design and population

This retrospective observational study included all the infants admitted to the neonatal

intensive care unit of Helsinki University Hospital (HUS), a level III/IV NICU with a

catchment area of approximately 18,000 deliveries per year, between January 1, 2009, and

March 31, 2024. Following the predefined exclusion criteria, the final follow-up cohort

consisted of 18,548 infants. All analyses were conducted using a secure research platform

(HUS Acamedic), which complies with national and EU General Data Protection Regulation.

HUS Helsinki University Hospital approved the study protocol (HUS/617/2025). Individual

consent was not required for this register study.

Clinical data

The dataset included maternal and neonatal demographic data, birth details, administered

medications, and diagnoses both from the initial hospitalization and long-term inpatient and

outpatient encounters within HUS Helsinki University Hospital.

Medications were identified with ATC-codes or generic names. Weight-adjusted cumulative

doses were calculated from medication administration data. Medication concentrations were

retrieved from laboratory data. Early diagnoses were identified by ICD-10 codes entered for

the NICU stay. Birth weight, gestational age, patient sex and mode of delivery were extracted

from birth records.

Hospital discharge was defined as the end date of the initial hospitalization record, after

which cumulative medication doses were computed. The follow-up times were calculated

from discharge to the diagnosis date, death or to the date of last contact with the patient

(censoring time).

A total of 34 patients with missing data in key variables such as birth weight, mode of

delivery, gender, or maternal identity were excluded from the final dataset.

Data were queried from the HUS Datalake which aggregates data from multiple patient

information systems. In the years 2009-2020 the NICU data were recorded in Centricity

Critical Care Clinisoft (GE Healthcare, Chicago, IL, USA), prenatal care and delivery

information in Obstetrix (Siemens, Sweden) and pediatric care in Uranus (CGI, Finland). In

2020, HUS transitioned to the EPIC patient information system (EPIC Systems, Verona, WI,

USA)

Outcomes

Neurological outcomes were determined using ICD-10 codes from follow-up visits. The

outcomes assessed included cerebral palsy, epilepsy, intellectual disability, autism spectrum

disorders and sensorineural defects consisting of visual impairment and hearing impairment.

The ICD-10 codes and the number of patients for each outcome are shown in Table 1. Due to

the small number of patients the association between ASM exposure and autism spectrum

disorder or hearing impairment could not be evaluated (Table 2).

Statistical Analysis

Multivariable cause-specific hazard Cox models were employed to examine the associations

between exposure to phenobarbital, levetiracetam, midazolam and fosphenytoin and the risk

of cerebral palsy, epilepsy, visual impairment and intellectual disability. The time-to-event

was defined using the follow-up time calculated earlier for each patient. Four separate models

were constructed for each medication-outcome pair. Potential dose–response relationships

were examined by including the medication use—defined as the total cumulative dose during

hospitalization—as a continuous variable in the Cox models. Sensitivity analyses were

conducted to account for possible nonlinear associations between medication exposure and

outcome hazard using restricted cubic splines.

The covariates adjusted for in the models for each outcome were determined by prior

knowledge of relevance. These included gestational age, birth weight, mode of birth, gender,

intraventricular hemorrhage (IVH), neonatal hypoxic-ischemic encephalopathy (HIE), birth

asphyxia, stroke, hospitalization time (age at discharge) and retinopathy of prematurity. IVH

and HIE were categorized into severe versus moderate/mild forms, and mode of delivery was

categorized as vaginal birth or cesarean section.

Analysis of multiple exposures

To account for 30% of patients receiving more than one ASM during their hospitalization,

each model was adjusted for co-exposure to other ASMs. Additionally, since phenobarbital is

used as the first-line ASM, exposure to multiple treatments may indicate poor response and

more difficult clinical condition. This in turn may lead to residual confounding when

comparing phenobarbital to other ASMs. Thus, to explore whether multiple ASM use was

associated with poorer outcomes, confounder-adjusted cumulative incidence functions were

estimated between patients exposed to phenobarbital and patients exposed to phenobarbital

and other ASMs using direct standardization.[25]

Phenobarbital blood concentration measurements

For patients with phenobarbital serum concentration measurements, we explored whether the

maximum concentration level was associated with adverse outcomes by fitting additional

models for each outcome. The models were adjusted to IVH, HIE and stroke only due to the

smaller sample size and number of outcomes in the patient subgroup.

Sensitivity Analysis

To evaluate the robustness of our modelling assumptions and data selection procedures, two

sensitivity analyses were conducted. Firstly, follow-up was restricted to 95th percentile of

event times for each outcome to examine whether late diagnoses potentially biased our

results. Secondly, cumulative doses were calculated only up to 28 days from birth, with

follow-up commencing from that time point. This was done to assess whether large

cumulative dose outliers accumulating for patients with longer hospitalization periods

influenced our results.

To account for within-family correlation due to siblings in the data, cluster-robust standard

errors were employed. The proportional hazards assumption was assessed visually with

Schoenfeld residual plots.[26] Variables that violated the assumption were either stratified with

or their coefficients were allowed to vary with time using a step function.

All statistical analyses were performed using R version 4.5.0 (R Statistical Computing

Foundation, Vienna, Austria) and packages *survival, rms, cmprsk* and *adjustedCurves.* All

statistical tests were two-sided and a P-value <0.05 was considered significant.

ChatGPT Version 1.2025.350 and Microsoft Copilot were used in order to refine the language

of the work.

Results

Patients and identification

A total of 24,145 infants admitted to the HUS NICU during the study period were initially

included. Infants who died before discharge, had missing data, were residents outside the

HUS catchment area, had no follow-up information or were born after 2023 were excluded,

leaving a final analytic cohort of 18,548 infants (Figure 1).

The demographic and clinical characteristics of the cohort are summarized in Table 2. The

median follow-up times calculated with reverse Kaplan-Meier estimators were 4.5 years

(average IQR: 1.6 – 9.2 years) for each diagnosis, with the follow-up times varying slightly

depending on the outcome. During the follow-up period, 196 cases of cerebral palsy, 252 of

epilepsy, 367 of intellectual disability, 387 of autism spectrum disorder, 344 of visual

impairment, and 220 of hearing impairment were identified. A total of 515 subjects received

any ASM with 370 subjects receiving one, 79 subjects two, 54 subjects three and 12 subjects

all four ASMs. The use of phenobarbital only (n = 193) was most common, followed by

midazolam only (n = 171), both phenobarbital and levetiracetam (n = 64) and a combination

of phenobarbital, levetiracetam and midazolam (n = 33).

Adjusted Hazard Ratios

Exposure to the median cumulative dose of phenobarbital was associated with increased

hazard ratio for epilepsy (HR 1.35; 95% CI, 1.11–1.62, p = 0.002) visual impairment (HR

1.20; 95% CI, 0.99–1.45, p = 0.06), and intellectual disability (HR 1.18; 95% CI, 0.99–1.41,

p = 0.06). Increased hazard ratio for cerebral palsy was not statistically significant (HR 1.13;

95% CI, 0.83–1.53, p = 0.44) (Table 3).

The adjusted hazard ratios associated with exposure to the median cumulative dose of

levetiracetam were on average smaller, but more precise, than those observed for

phenobarbital (Table 3). Levetiracetam was associated with increased hazard ratios for

cerebral palsy (HR 1.13; 95% CI, 1.03–1.23 *p* = 0.006), epilepsy (HR 1.14; 95% CI, 1.05–

1.24; *p* = 0.002) and visual impairment (HR 1.18; 95% CI, 1.11–1.26; *p* < 0.001) The hazard

ratio for intellectual disability was not statistically significant (HR 1.08; 95% CI, 0.98–1.19;

p = 0.14).

Midazolam administration demonstrated fewer adverse effects than levetiracetam and

phenobarbital. Midazolam exposure was significantly associated with intellectual disability

(HR 1.09; 95%, CI 1.02–1.16, p = 0.01). The HRs for cerebral palsy was 1.03 (95%, CI 0.89–

1.20, p = 0.74), epilepsy 1.06 (95% CI, 0.97–1.16, p = 0.20), and visual impairment 1.00

(95% CI, 0.85–1.18. p = 0.97).

The HRs for fosphenytoin were larger for epilepsy, 1.62 (95% CI, 0.82–3.21. p = 0.14) and

visual impairment, 1.87 (95% CI, 0.95–3.69 p = 0.07) than those of the other ASMs, but as

the use of fosphenytoin was rare, the uncertainty related to the estimates was large and the

results were not statistically significant.

Multiple Anti-seizure Medications

The unadjusted Aalen-Johansen estimates indicated notable differences between outcome

risks and the use of multiple ASMs compared to phenobarbital only, whereas the adjusted

estimates did not (Figure 2). For example, after three years of follow-up, the adjusted

cumulative incidences of cerebral palsy were 5.6% (95% CI, 3.2%-10.6%) for patients treated

with phenobarbital and second-line ASMs, 4.6% (95% CI, 2.7%-7.3%) for patients treated

with phenobarbital only and 0.66% (95% CI, 0.53%-0.81%) for patients with no ASM

exposure. The corresponding unadjusted estimates were 35.5% (95% CI, 27.4%-43.6%),

17.1% (95% CI, 11.6%-22.7%) and 0.64% (95% CI, 0.51%-0.77%), respectively.

Although patients exposed to both phenobarbital and other ASMs showed higher unadjusted

incidences of cerebral palsy, epilepsy, visual impairment and intellectual disability, adjusted

analyses did not provide evidence of worse outcomes after accounting for confounders and

the uncertainty in the estimates.

Phenobarbital Concentrations

Measured serum phenobarbital concentrations were available for 332 patients, enabling us to

examine the relationship between concentration and clinical outcomes. In this subgroup, the

hazard ratios for 50 µmol/l increase in maximum phenobarbital blood concentration

associated with elevated hazard ratios for cerebral palsy (HR 1.48; 95% CI, 1.07–2.06, p =

0.02) and epilepsy (HR 1.64; 95% CI, 1.14–2.35, p = 0.007). No evidence for similar effect

was found for visual impairment (HR 1.10; 95% CI, 0.71–1.70, p = 0.69) or intellectual

disability (HR 1.08; 95% CI, 0.72–1.64, p = 0.71).

Sensitivity Analysis

We evaluated the sensitivity of our results to: (1) excluding diagnoses classified as late by

restricting the follow-up, (2) restricting the patient information to the neonatal period to

eliminate large cumulative doses accumulated over longer hospitalization periods, and (3)

assessed potential non-linear associations between the ASM use and the outcomes using

restricted cubic splines. Restricting the follow-up did not affect the results but restricting the

cumulative doses to the neonatal period or using restricted cubic splines increased the hazard

ratios for phenobarbital (see Supplementary Material).

Discussion

We found that exposure to phenobarbital in the neonatal intensive care unit was associated

with elevated risk of adverse long term neurological outcomes, including epilepsy (HR 1.35;

95% CI, 1.11–1.62, p = 0.002), visual impairment (HR 1.20; 95% CI, 0.99–1.45, p = 0.06),

and intellectual disability (HR 1.18; 95% CI, 0.99–1.41, p = 0.06). These findings are

consistent with data from animal models and previous clinical studies[13,14] and they reinforce

concerns regarding potential long-term neurodevelopmental consequences of phenobarbital

exposure in the neonatal period. Levetiracetam showed a more favorable profile, although it

was still associated with a modest increase in risk, with hazard ratios around 1.1. In a recent

systematic review, phenobarbital was concluded to be probably more effective than

levetiracetam in achieving seizure control after first loading dose and after maximal loading

dose, but data on mortality before discharge, mechanical ventilation and epilepsy post-

discharge were uncertain.[3] A recent meta-analysis on efficacy and safety of levetiracetam

versus phenobarbital found no significant difference in the efficacies, but levetiracetam had a

more favorable adverse effect profile than phenobarbital.[27] Midazolam was also associated

with lower hazard ratios for long term problems than phenobarbital, but its potent sedative

effect often limits its use to third-line drug in treating neonatal seizures.

Although a significant relationship was observed between exposure to phenobarbital and

neurologic outcomes, the sensitivity analyses showed that the cumulative dose did not offer

extra insight into outcome risk for exposed patients. We did not consequently find evidence

of a dose-dependent effect of phenobarbital (see Supplementary Material). This may reflect

the relatively short courses administered, as the median cumulative dose was 28.4 mg/kg

compared with a recommended initial loading dose of 20 mg/kg. This finding is consistent

with the study by Saxena et al., in which infants receiving a loading dose of phenobarbital for

seizure control and randomized to either short-term maintenance therapy or no maintenance

therapy showed comparable risks of abnormal neurological assessment at 24 months of age.[28]

Increased maximum serum phenobarbital concentrations were associated with elevated

hazard ratios for cerebral palsy and epilepsy. This could reflect a toxic effect after higher

phenobarbital concentrations, while larger cumulative doses might not increase the risk as

long as maximum concentrations remain at a lower level. Individual variation on

phenobarbital pharmacokinetics could also play a role.[29]

This study has several limitations. The main problem pertains to distinguishing the effect of

the underlying clinical problem that prompted seizures and ASM use from detrimental effect

of the treatment. Previous studies have also struggled with the same problem. Typical

etiologies (hypoxic-ischemic encephalopathy, ischemic stroke, and intracranial hemorrhage)

are associated with both short and long term neurological problems and while we adjusted

our analysis for these diagnoses, some effect may have persisted. The different models used

in this study produced varying hazard ratios and we chose to present most conservative

estimate. We believe that the comparisons between patients exposed to different ASMs may

partly circumvent the problem. Still, phenobarbital use as a first-line treatment may have

been skewed towards more benign clinical cases, and second- and third-line drugs to more

severe cases, and we therefore addressed this by the multiple ASM analysis. Despite this

potential bias, our study revealed that phenobarbital exhibited worse hazard ratios for

cerebral palsy, epilepsy and visual impairment compared to levetiracetam or midazolam.

Fosphenytoin was used too rarely for reliable analyses.

The reliability of our results is increased by the fact that the data are population-based and

derived from a single center. The Helsinki University Hospital (HUS) catchment area

encompasses approximately 1.7 million residents and 18,000 deliveries per year, with all

infants requiring neonatal intensive care treated at the New Children's Hospital NICU.

Children requiring specialized pediatric or child neurological care are followed within HUS

hospitals, and diagnostic data were available for 18,548 of 19,940 eligible children (93%).

Conclusion

Using real-world data and long-term follow-up in a comprehensive population-based sample

of infants treated with ASMs we showed exposure to phenobarbital to be associated with

increased hazard ratios for epilepsy, visual impairment, and intellectual disability. These

results align with previous findings linking phenobarbital to neurodevelopmental harm and

emphasize the need for its cautious use in neonates. Levetiracetam had more favorable safety

profile.

Acknowledgments

This project received funding from institutional sources of HUS, The Association of Friends of the University Children's Hospitals (Lastenklinikoiden Kummit ry) and The Foundation for Pediatric Research, Finland. We wish to acknowledge the support of Mona Halme, Mira Kilpi, and Mira Kuusinen from the Children and Adolescents' Data Services Team at Helsinki University Hospital (HUS). ChatGPT Version 1.2025.350 and Microsoft Copilot were used in order to refine the language of the work.

References

1. Gade C, Trolle S, Mørk M, et al. Massive presence of off□label medicines in Danish neonatal departments: A nationwide survey using national hospital purchase data. *Pharmacol Res Perspect*. 2023;11(1):e01037. doi:10.1002/prp2.1037

2. Barr J, Brenner-Zada G, Heiman E, et al. Unlicensed and Off-Label Medication Use in a Neonatal Intensive Care Unit: A Prospective Study. *Am J Perinatol*. 2002;19(2):067-072. doi:10.1055/s-2002-23557

3. Abiramalatha T, Thanigainathan S, Ramaswamy VV, Pressler R, Brigo F, Hartmann H. Anti□seizure medications for neonates with seizures. *Cochrane Database Syst Rev*. 2023;2023(10):CD014967. doi:10.1002/14651858.cd014967.pub2

4. Gettings JV, Soul JS. Updates in Neonatal Seizures. *Clin Perinatol*. 2025;52(2):375-393. doi:10.1016/j.clp.2025.02.008

5. Pressler RM, Abend NS, Auvin S, et al. Treatment of seizures in the neonate: Guidelines and consensus□based recommendations—Special report from the ILAE Task Force on Neonatal Seizures. *Epilepsia*. 2023;64(10):2550-2570. doi:10.1111/epi.17745

6. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital Compared with Phenytoin for the Treatment of Neonatal Seizures. *N Engl J Med*. 1999;341(7):485-489. doi:10.1056/nejm199908123410704

7. Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. *Pediatrics*. 2020;145(6):e20193182. doi:10.1542/peds.2019-3182

8. Long D, Sutton C, Hale J. Efficacy of Levetiracetam vs Phenobarbital as First Line Therapy for the Treatment of Neonatal Seizures. *J Pediatr Pharmacol Ther*. 2024;29(5):482-486. doi:10.5863/1551-6776-29.5.482

9. Bättig L, Dünner C, Cserpan D, et al. Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study. *Pediatr Neurol*. 2023;138:62-70. doi:10.1016/j.pediatrneurol.2022.10.004

10. Kaushal S, Tamer Z, Opoku F, Forcelli PA. Anticonvulsant drug–induced cell death in the developing white matter of the rodent brain. *Epilepsia*. 2016;57(5):727-734. doi:10.1111/epi.13365

11. Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. *Proc Natl Acad Sci*. 2002;99(23):15089-15094. doi:10.1073/pnas.222550499

12. Forcelli PA, Kim J, Kondratyev A, Gale K. Pattern of antiepileptic drug–induced cell death in limbic regions of the neonatal rat brain. *Epilepsia*. 2011;52(12):e207-e211. doi:10.1111/j.1528-1167.2011.03297.x

13. Falsaperla R, Mauceri L, Pavone P, et al. Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience. *Behav Neurol*. 2019;2019(1):1-8. doi:10.1155/2019/3683548

14. El-Dib M, Soul JS. The use of phenobarbital and other anti-seizure drugs in newborns. *Semin Fetal Neonatal Med*. 2017;22(5):321-327. doi:10.1016/j.siny.2017.07.008

15. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for Febrile Seizures — Effects on Intelligence and on Seizure Recurrence. *N Engl J Med*. 1990;322(6):364-369. doi:10.1056/nejm199002083220604

16. Meyn DF, Ness J, Ambalavanan N, Carlo WA. Prophylactic Phenobarbital and Whole-Body Cooling for Neonatal Hypoxic-Ischemic Encephalopathy. *J Pediatr*. 2010;157(2):334-336. doi:10.1016/j.jpeds.2010.04.005

17. Donovan MD, Griffin BT, Kharoshankaya L, Cryan JF, Boylan GB. Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives. *Drugs*. 2016;76(6):647-661. doi:10.1007/s40265-016-0554-7

18. Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. *J Perinatol*. 2013;33(11):841-846. doi:10.1038/jp.2013.116

19. Hughes S, Blumenthal M, Johnson A, Limjoco J, Lim SY. Pharmacokinetics and Pharmacodynamics of Levetiracetam in Neonatal Seizures: What We Still Need to Know. *J Pediatr Pharmacol Ther*. 2025;30(2):170-181. doi:10.5863/1551-6776-30.2.170

20. Ahmad KA, Desai SJ, Bennett MM, et al. Changing antiepileptic drug use for seizures in US neonatal intensive care units from 2005 to 2014. *J Perinatol*. 2017;37(3):296-300. doi:10.1038/jp.2016.206

21. Zeller B, Giebe J. Pharmacologic Management of Neonatal Seizures. *Neonatal Netw*. 2015;34(4):239-244. doi:10.1891/0730-0832.34.4.239

22. Glass HC, Kan J, Bonifacio SL, Ferriero DM. Neonatal Seizures: Treatment Practices Among Term and Preterm Infants. *Pediatr Neurol*. 2012;46(2):111-115. doi:10.1016/j.pediatrneurol.2011.11.006

23. Ng E, Taddio A, Ohlsson[a] A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. *Cochrane Database Syst Rev*. 2017;1(1):CD002052. doi:10.1002/14651858.cd002052.pub3

24. Arya V, Ramji S. Midazolam sedation in mechanically ventilated newborns: a double blind randomized placebo controlled trial. *Indian Pediatr*. 2001;38(9):967-972.

25. Denz R, Klaaßen Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. *Stat Med*. 2023;42(10):1461-1479. doi:10.1002/sim.9681

26. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994;81(3):515-526. doi:10.1093/biomet/81.3.515

27. Salim N, Qadri SI, Chughtai MAI, et al. Efficacy and safety of levetiracetam versus phenobarbitone for neonatal seizures: A systemic review and meta-analysis. *Clin Neurol Neurosurg*. 2025;258:109155. doi:10.1016/j.clineuro.2025.109155

28. Saxena P, Singh A, Upadhyay A, Gupta P, Sharma S, Vishnubatla S. Effect of Withholding Phenobarbitone Maintenance in Neonatal Seizures: A   Randomized Controlled Trial. *Indian Pediatr*. 2016;53:1069-1073.

29. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone. *Eur J Clin Pharmacol*. 2000;55(11-12):821-825. doi:10.1007/s002280050703

Figure legends

Figure 1: Patient flowchart

Figure 2: Adjusted cumulative incidences and 95 % bootstrap intervals based on 500 bootstrap samples for patients treated with phenobarbital and other ASMs.

Alt Texts

Figure 1: Flowchart showing patient selection, reasons for exclusion, and numbers of patients in each group.

Figure 2: Line plot showing adjusted cumulative incidences of cerebral palsy, epilepsy, visual impairment and intellectual disability as a function of time after hospital discharge in patients treated with phenobarbital or phenobarbital and other ASMs or no exposure to ASMs

Table 1: Table listing neurological outcomes studied in the paper, their ICD-10 codes and number of cases. Most common outcomes were autism spectrum disorder with 387 cases and intellectual disability with 367 cases.

Table 2: Table showing patient demographics, early diagnosis and later neurological morbidities in all study patients and patients exposed to phenobarbital, levetiracetam, midazolam, and fosphenytoin .

Table 3: Table showing hazard ratios to cerebral palsy, epilepsy, visual impairment and intellectual disability in patients exposed median cumulative dose of phenobarbital, levetiracetam, midazolam, or fosphenytoin. Highest statistically significant hazard ratio was 1.35 for epilepsy in patients exposed to phenobarbital.

Table 1 Neurological outcomes

Major neurologigal morbidities	ICD-10 codes	N
Cerebral palsy	G80.0–G80.9	196
Epilepsy	G40.0–G40.9	252
Intellectual disability	F70.0–F73.9 and F78.0–F79.9	367
Autism spectrum disorder	F84.0–F84.9	387
Visual impairment	H53.0–H53.4 and H54.0–H54.7	344
Hearing impairment	H90.0–H90.8	220

Table 2 Patient demographics

	All	Phenobarbital	Levetiracetam	Midazolam	Fosphenytoin
N	18548	336	136	229	37
Patient demographics					
Male	10 261 (55.3 %)	182 (54.2%)	71 (52%)	133 (58.1%)	22 (60 %)
Birth weight (Kg, Mean, SD)	3.00 ± 0.93	3.17±0.91	3.13±0.79	3.12 ± 0.77	3.17 ± 0.63)
Gestational age (Weeks, Mean, SD)	37.4 ± 3.65	38.4 ± 3.9	38.6 ± 3.25	38.7 ± 2.95	38.9 ± 2.48
Vaginal delivery	9892 (53.3 %)	168 (50.0%)	55 (40 %)	129 (56.3 %)	19 (51%)
Hospitalization time (Days, Median, IQR)	5.4 (3.4-12.7)	14.1 (9.0-28.7)	16.0 (10.7-27.0)	27.5 (19.2-53.8)	13.6 (10.0-20.7)
Cumulative dose (mg/kg, Median, IQR)		28.4 (20.0-37.3)	98.6 (30.4-203.6)	2.5 (0.7-6.9)	23.8 (20.6-31.3)
Early diagnoses (ICD-10)					
Severe birth asphyxia (P21.0)	362 (2.0%)	124 (36.9%)	52 (38 %)	34 (14.8)	9 (24%)
Mild and moderate birth asphyxia (P21.1)	984 (5.3%)	40 (11.9%)	12 (9 %)	5 (2.2)	4 (11%)
Cerebral ischemia (P91.08)	80 (0.4%)	59 (17.6%)	42 (31%)	9 (3.9)	17 (46%)
Mild hypoxic-ischemic encephalopathy (P91.00)	82 (0.4%)	14 (4.2%)	< 3	< 3	< 3
Moderate hypoxic-ischemic encephalopathy (P91.01)	95 (0.5%)	54 (16.1%)	16 (12%)	11 (4.8)	4 (11%)
Severe hypoxic-ischemic encephalopathy (P91.02)	47 (0.3%)	44 (13.1%)	32 (24%)	19 (8.3)	7 (19%)
Intraventricular hemorrhage, grade 1 (P52.0)	223 (1.2%)	5 (1.5%)	< 3	3 (1.3)	< 3
Intraventricular hemorrhage, grade 2 (P52.1)	128 (0.7%)	3 (0.9%)	< 3	5 (2.2)	< 3
Intraventricular hemorrhage, grade 3 and grade 4 (P52.2)	108 (0.6%)	19 (5.7%)	10 (7%)	4 (1.7)	< 3
Later morbidites (ICD-10)					
Cerebral palsy (G80-G80.9)	196 (1.1%)	85 (25.3%)	53 (38%)	26 (11.4)	14 (38%)
Epilepsy (G40-G40.9)	252 (1.4%)	57 (17.0%)	36 (27%)	19 (8.3)	10 (27%)
Intellectual disability (F70.0-F73.9 and F78.0-F79.9	367 (2.0%)	49 (14.6%)	25 (18%)	28 (12.2)	6 (16%)
Autism spectrum disorder (F84-F84.9)	387 (2.1%)	13 (3.9%)	6 (4%)	9 (3.9)	< 3
Visual impairment (H53-H54 and H54.0-H54.7)	344 (1.9%)	42 (12.5%)	24 (18%)	18 (7.9)	7 (19%)
Hearing impairment (H90-H90.8)	220 (1.2%)	15 (4.5%)	8 (6%)	15 (6.6)	< 3

Data are n (%) or mean (SD). If there were less than 3 patients, <3 is shown instead of exact number.

Table 3: Hazard ratios and 95 % Confidence Intervals.

	Cerebral Palsy[1]	Epilepsy[1]	Visual Impairment[2]	Intellectual Disability[3]
Phenobarbital	1.13 [0.83, 1.53] P = 0.44	1.35 [1.11, 1.62] P = 0.002	1.20 [0.99, 1.45] P = 0.06	1.18 [0.99, 1.41] P = 0.06
Levetiracetam	1.13 [1.03, 1.23] P = 0.006	1.14 [1.05, 1.24] P = 0.002	1.18 [1.11, 1.26] P <0.0001	1.08 [0.98, 1.19] P = 0.14
Midazolam	1.03 [0.89, 1.20] P = 0.74	1.06 [0.97, 1.16] P = 0.20	1.00 [0.85, 1.18] P = 0.97	1.09 [1.02, 1.16] P =0.01
Fosphenytoin	0.900 [0.36, 2.25] P = 0.81	1.62 [0.82, 3.21] P = 0.14	1.87 [0.95, 3.69] P = 0.07	1.10 [0.49, 2.43] P =0.82

1 Adjusted for gestational age, birth weight, hospitalisation time, mode of delivery, gender, IVH, HIE, stroke and birth asphyxia.
2 Adjusted for gestational age, birth weight, hospitalisation time, mode of delivery, gender, IVH, HIE, stroke, birth asphyxia and retinopathy of prematurity.
3 Adjusted for gestational age, birth weight, hospitalisation time, mode of delivery, gender, IVH, HIE and birth asphyxia.

Hazard ratios are reported for patients receiving the median positive cumulative dose for each medication, when the reference is a patient with no exposure. No statistical corrections for multiple testing were applied to the reported P-values.